A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for so long has defined generics pricing. Yet this revolution also has the potential to eliminate players from the market entirely, especially those who remain stuck in outdated business models. With every passing year, the message becomes clearer: pharmaceutical companies operating in the generics space must change the way they do business — or die. Read More >